Piclidenoson Shows Promise for Lowe Syndrome in Study

Preclinical research published in Signal Transduction and Targeted Therapy points to a possible treatment path for a rare genetic kidney disorder.

Updated on Nov. 12, 2026 in Life Sciences

Piclidenoson Shows Promise for Lowe Syndrome in Study

Can-Fite BioPharma reports that its compound piclidenoson restored protein reabsorption in preclinical Lowe syndrome models, including patient-derived kidney cells, human kidney organoids and a humanized mouse model. The research was led by the Telethon Institute of Genetics and Medicine and the University of Naples Federico II.

Why it matters

Lowe syndrome, a rare disorder affecting the eyes, brain and kidneys, currently has no curative therapy available. The findings add early evidence for a compound already being evaluated in other clinical programs.

The evidence comes from preclinical models, where a urinary protein marker fell 48-80% in treated mice compared with untreated disease-model mice after five months of therapy. Human efficacy remains unknown, and the planned Phase II study in five adult patients is still awaiting regulatory review.

The players

Can-Fite BioPharma Ltd.

An Israeli drug developer headquartered in Ramat Gan that is evaluating piclidenoson across several clinical programs, including psoriasis.

Telethon Institute of Genetics and Medicine (TIGEM)

A Naples-based genetics research institute supported by Fondazione Telethon that co-led the Lowe syndrome study.

The details

Researchers screened 1,280 compounds and identified piclidenoson, which activates the A3 adenosine receptor and corrects abnormal lipid accumulation in Lowe syndrome kidney cells. The compound restored cellular protein trafficking and reabsorption in the models tested. A Phase II clinical study has been designed to evaluate oral piclidenoson twice daily for six months in five adult patients with genetically confirmed Lowe syndrome.

Timeline

  1. November 12, 2026: Can-Fite announced publication of the Lowe syndrome research.

  2. First quarter of 2027: Interim efficacy and safety data from the Phase III psoriasis study are expected.

Health Landscape

The work reflects the rare-disease research model led by Fondazione Telethon, which has funded 2,960 projects with 660 million euros. It shows how drug repurposing screens can move compounds toward treatments for conditions with no curative options.

For families affected by Lowe syndrome, this research offers early evidence of a possible therapy where none is currently available. Any real-world access will depend on the outcome of clinical testing and regulatory review.

The takeaway

Early preclinical findings can narrow the search for treatments in rare genetic diseases with few options. Patients and families should watch for clinical trial results before drawing conclusions about any therapy.

What happens next

A Phase II clinical study of piclidenoson in Lowe syndrome is under review by Italian Health Authorities, and Phase III psoriasis interim data are expected in the first quarter of 2027.

Further reading

Explore more Life Sciences research and discoveries shaping rare-disease treatment.

More information

Read the published study in Signal Transduction and Targeted Therapy for the full methods and results.

Source note: This article includes information reported by The Manila times.